Qiagen agreed to acquire Parse Biosciences for $225 million in cash plus up to $55 million in milestones, a move to bring instrument‑free single‑cell sample‑prep into its portfolio. The announcement accompanied Qiagen’s strong Q3 results and a leadership transition, according to the company release and earnings coverage. Qiagen said Parse’s scalable, instrument‑free technology complements its sample and informatics strategy and will accelerate offerings for pharma customers and research labs. Single‑cell genomics remains a fast‑growing area; the deal signals consolidation as larger vendors buy into platforms that lower barriers to entry for broad multisite adoption.